Open AccessCardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials
Author(s) -
Scott D. Solomon,
Janet Wittes,
Peter Finn,
Robert Fowler,
Jaye L. Viner,
Monica M. Bertagnolli,
Nadir Arber,
Bernard Levin,
Curtis L. Meinert,
Barbara K. Martin,
Joseph L. Pater,
Paul E. Goss,
Peter Lance,
Stefanie Obara,
Emily Y. Chew,
Jonghyeon Kim,
Gretchen Arndt,
Ernest T. Hawk
Publication year - 2008
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.108.764530
Subject(s) - celecoxib , medicine , hazard ratio , placebo , myocardial infarction , randomized controlled trial , clinical endpoint , regimen , stroke (engine) , confidence interval , mechanical engineering , alternative medicine , pathology , engineering
Observational studies and randomized trials have reported increased cardiovascular risk associated with cyclooxygenase-2 inhibitors. Prior placebo-controlled randomized studies had limited ability to assess the relationship of either celecoxib dose or pretreatment cardiovascular status to risk associated with celecoxib. Our aim was to assess the cardiovascular risk associated with celecoxib in 3 dose regimens and to assess the relationship between baseline cardiovascular risk and effect of celecoxib on cardiovascular events.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom